Caplight Directory>Companies>VALANX Biotech-preview>Valanx


VALANX Biotech

VALANX Biotech

Private
ViennaHealthcare & Life Scienceshttps://www.valanx.bio/

Last Round

Series A

Mar 12, 2026

Total Funding Raised

$3.55M

Company Overview

VALANX Biotech is a biotechnology company that has developed a proprietary platform for site-specific protein conjugation to create antibody-drug conjugates (ADCs) and other biologics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugatesADCsite-specific protein conjugationbioconjugationbiotech platformclick chemistryprotein engineeringcancer therapydrug discoverybiotherapeuticsplatform licensingsynthetic biologyvaccine developmentcarrier protein

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

VALANX Biotech Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

VALANX Biotech Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AMar 12, 2026
VC RoundNov 7, 2023
SeedMay 1, 2020
AcceleratorJun 16, 2017
View all Funding Rounds

VALANX Biotech Investors

Notable investors and investment history

InvestorRounds
tecnet equitySeed, Series A, VC Round
SkygeneSeries A, VC Round
xista science venturesSeed, VC Round
xista science venturesSeries A
RebelBioAccelerator
SOSVSeed, Series A, VC Round, Accelerator
Fondation Fournier-MajoieSeries A
View all Investors

VALANX Biotech Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

VALANX Biotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about VALANX Biotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersVienna
Employee Range14
Year Founded2017
Last FundingMar 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.